Home

Test: C-Reactive Protein (CRP)

C-reactive protein (CRP) is an important and evolutionarily ancient component of the innate immune responseThe body's first line of defense against intracellular and other pathogens. According to the Marshall Pathogenesis the innate immune system becomes disabled as patients develop chronic disease..1) CRP has been described as “the prototypical acute-phase reactant to infections and inflammationThe complex biological response of vascular tissues to harmful stimuli such as pathogens or damaged cells. It is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue. in human beings.” In the clinical setting, CRP is used “as a clinical indicator of acute infections and response to treatment, and to assess inflammatory status in chronic diseases.”2) Initially it was thought that CRP might be a pathogenic secretion as it was elevated in people with a variety of illnesses including cancer.3) However, discovery of synthesis in the liver demonstrated that it is manufactured by the human body.

The fact that CRP is an independent predictor of stroke and coronary artery disease but also a key contributor to effective bacterial clearance,4) underscores the importance of microbes in the pathogenesis of these diseases. Some patients on the Marshall ProtocolA curative medical treatment for chronic inflammatory disease. Based on the Marshall Pathogenesis. (MP) have reported temporary increases in CRP, an observation which is consistent with a heightened immune response.

CRP's name comes from its capacity to bind the C-polysaccharide of Streptococcus pneumoniae, which provides innate defense against pneumococcal infection.5)

Interpreting high CRP

An elevated CRP is something that is expected to be seen in many MP patients because it's a direct indicator of an inflammatory response to infection. The experience of Autoimmunity Research FoundationNon-profit foundation dedicated to exploring a pathogenesis and therapy for chronic disease. has, thus far, shows that as long as immunopathologyA temporary increase in disease symptoms experienced by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed. is tolerable while CRP remains high, there's no need to make any changes in dosing of the MP medications. However, physicians and patients should always assess if immunopathology is too strong. If this is the case, taking measures to reduce immunopathology is always recommended. Patients with cardiac disease may want to be particularly careful about assessing the level of immunopathology when their CRP goes out of range.

Function

C-reactive protein plays a key role in the body's immune response to pathogenic microbes. Source: Wikipedia

C-reactive protein is an acute phase reactant (that is, a substance rapidly produced after infection or tissue damage) with roles including:

  • innate host defense – promotes phagocytosis by opsonizing bacteria (i.e. coating the microbe with antibodies or a complement protein so as to make it palatable to phagocytes)
  • clearance of damaged cells – binds phosphocholine expressed on the surface of dead or dying (i.e. apoptotic, necrotic) human and bacterial cells
  • regulation of the inflammatory response – may act through Fcgamma receptors to reduce inflammation and protect from certain autoimmune diseases6)

During the acute phase response, levels of CRP rapidly increase up to 1000-fold, reaching a peak at 48 hours. With resolution of the acute phase response, CRP declines with a relatively short half-life of 18 hours.7)

Demonstrated antimicrobial activity against gram-negative bacteria

CRP has been shown to be generated in response to several gram-negative species of bacteria including:

  • Chlamydia pneumoniae – Johnson et al. showed that the presence of viable C. pneumoniae in patients who underwent endarterectomy for carotid artery stenosis independently predicted C-reactive protein levels.8)
  • Psuedomonas aeruginosa – Ng et al. used a horseshoe crab animal model to demonstrate that serum levels of CRP are upregulated by about 60-fold in 6-48 hours after infection with the gram-negative bacterial pathogen, P. aeruginosa.9)

Of course, one of the structural components of gram-negative bacteria are endotoxins, the bioavailability of which leads to the immunopathological reactionA temporary increase in disease symptoms experiences by Marshall Protocol patients that results from the release of cytokines and endotoxins as disease-causing bacteria are killed. as described by the Marshall PathogenesisA description for how chronic inflammatory diseases originate and develop..

Predictor of cardiovascular disease

C-reactive protein is a predictor of:

  • long-term risk of heart attack and stroke in apparently healthy men and women10) 11) 12)
  • risk of cardiovascular events in patients with coronary artery disease13)
  • development of hypertension14)

The association between serum C-reactive protein levels and subsequent risk of stroke, heart attack, and death from cardiac causes supports the importance of inflammation and chronic infection in the pathogenesis of cerebrovascular and coronary artery disease.15) 16)

Because there are a large number of disparate conditions that can induce CRP production, an elevated CRP level does not have diagnostic specificity.17)

A more sensitive CRP test, called a highly sensitive C-reactive protein (hs-CRP) assay, is available to determine heart disease risk.

Other diseases

In addition to the blood serum, CRP has also been detected in the cerebrospinal fluid,18) which suggests the protein could be secreted in response to microbial infection.

CRP also tends to be associated with other chronic inflammatory diseases including rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, and psoriatic arthritis. While elevated levels of CRP are an indication of ongoing infection and inflammation of many such diseases, it is certainly not present in all diseases. For example, conditions such as systemic lupus erythematosus, ulcerative colitis, and scleroderma tend to present with modest, if not absent, increases in CRP.19)

Ultimately, the absence of CRP as a sensitive marker for inflammatory disease may parallel the inconsistency with which any one species of pathogen is found in chronic disease. It would appear that the body employs a variety of mechanisms for responding to infection, only one of which is the production of CRP.

Read more

Notes and comments

  • Legacy content
    • s73:

Higher levels are found in late pregnant women, mild inflammation and viral infections (10–40 mg/L), active inflammation, bacterial infection (40–200 mg/L), severe bacterial infections and burns (>200 mg/L).[6]

J Emerg Med. 1999 Nov-Dec;17(6):1019-25. The C-reactive protein. Clyne B, Olshaker JS.

Department of Surgery, University of Maryland Medical System, Baltimore 21201, USA. Abstract C-reactive protein (CRP) was identified in 1930 and was subsequently considered to be an “acute phase protein,” an early indicator of infectious or inflammatory conditions. Since its discovery, CRP has been studied as a screening device for inflammation, a marker for disease activity, and as a diagnostic adjunct. Improved methods of quantifying CRP have led to increased application to clinical medicine. In the emergency department (ED), CRP must be interpreted in the clinical context; no single value can be used to rule in or rule out a specific diagnosis. We conclude that CRP has limited utility in the ED. It may be a useful adjunct to serial examinations in equivocal presentations of appendicitis in those centers without ready access to computed tomography (CT) scan. It may be elevated with complications or treatment failures in patients with pneumonia, pancreatitis, pelvic inflammatory disease (PID), and urinary tract infections. In patients with meningitis, neonatal sepsis, and occult bacteremia, CRP is usually elevated. However, CRP has no role in diagnosing these clinical entities, and a normal CRP level should never delay antibiotic coverage.

PMID: 10595891

July 13, 2011CRP May Have Role in Predicting Breast Cancer Outcomes

Am J Cardiol. 2011 Oct 12. [Epub ahead of print] Relation Between Serum 25-Hydroxyvitamin D and C-Reactive Protein in Asymptomatic Adults (From the Continuous National Health and Nutrition Examination Survey 2001 to 2006). Amer M, Qayyum R. Source Johns Hopkins University School of Medicine, Baltimore, Maryland. Abstract The inverse relation between vitamin D supplementation and inflammatory biomarkers among asymptomatic adults is not settled. We hypothesized that the inverse relation is present only at lower levels and disappears at higher serum levels of vitamin D. We examined the relation between 25-hydroxyvitamin D [25(OH)D] and C-reactive protein (CRP) using the continuous National Health and Nutrition Examination Survey data from 2001 to 2006. Linear spline [single knot at median serum levels of 25(OH)D] regression models were used. The median serum 25(OH)D and CRP level was 21 ng/ml (interquartile range 15 to 27) and 0.21 mg/dl (interquartile range 0.08 to 0.5), respectively. On univariate linear regression analysis, CRP decreased [geometric mean CRP change 0.285 mg/dl for each 10-ng/ml change in 25(OH)D, 95% confidence interval [CI] -0.33 to -0.23] as 25(OH)D increased ≤21 ng/ml. However, an increase in 25(OH)D to >21 ng/ml was not associated with any significant decrease [geometric mean CRP change 0.05 mg/dl for each 10-ng/ml change in 25(OH)D, 95% CI -0.11 to 0.005) in CRP. The inverse relation between 25(OH)D below its median and CRP remained significant [geometric mean CRP change 0.11 mg/dl for each 10-ng/ml change in 25(OH)D, 95% CI 0.16 to -0.04] on multivariate linear regression analysis. Additionally, we observed a positive relation between 25(OH)D above its median and CRP [geometric mean CRP change 0.06 mg/dl for each 10-ng/ml change in 25(OH)D, 95% CI 0.02 to 0.11) after adjusting for traditional cardiovascular risk factors. In conclusion, from this cohort of asymptomatic adults, independent of traditional cardiovascular risk factors, we observed a statistically significant inverse relation between 25(OH)D at levels <21 ng/ml and CRP. We found that 25(OH)D at a level ≥21 ng/ml is associated with an increase in serum CRP. It is possible that the role of vitamin D supplementation to reduce inflammation is beneficial only among those with a lower serum 25(OH)D. Copyright © 2011 Elsevier Inc. All rights reserved.

PMID: 21996139

References

2)
Innate microbial sensors and their relevance to allergy.
Liu AH
J Allergy Clin Immunol122p846-58; quiz 858-60(2008 Nov)
3) , 5) , 19)
C-reactive protein: a critical update.
Pepys MB, Hirschfield GM
J Clin Invest111p1805-12(2003 Jun)
4)
The antimicrobial properties of C-reactive protein (CRP).
Tan SS, Ng PM, Ho B, Ding JL
J Endotoxin Res11p249-56(2005)
7)
Current rheumatology diagnosis & treatment. 2007. New York, Lange Medical Books/McGraw-Hill, Medical Pub. Division.
8)
C-reactive protein levels and viable Chlamydia pneumoniae in carotid artery atherosclerosis.
Johnston SC, Messina LM, Browner WS, Lawton MT, Morris C, Dean D
Stroke32p2748-52(2001 Dec 1)
11)
Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women.
Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH
Circulation98p731-3(1998 Aug 25)
12)
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH
N Engl J Med336p973-9(1997 Apr 3)
13) , 16)
Inflammatory markers of coronary risk.
Rader DJ
N Engl J Med343p1179-82(2000 Oct 19)
14)
C-reactive protein and the risk of developing hypertension.
Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM
JAMA290p2945-51(2003 Dec 10)
15)
Atherosclerosis--an inflammatory disease.
Ross R
N Engl J Med340p115-26(1999 Jan 14)
17)
Narrative review: Assessment of C-reactive protein in risk prediction for cardiovascular disease.
Lloyd-Jones DM, Liu K, Tian L, Greenland P
Ann Intern Med145p35-42(2006 Jul 4)
home/tests/crp.txt · Last modified: 01.09.2012 by paulalbert
© 2015, Autoimmunity Research Foundation. All Rights Reserved.